Current Report Filing (8-k)
December 14 2020 - 04:32PM
Edgar (US Regulatory)
false000080592800008059282020-12-142020-12-14
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): December 14, 2020
AXOGEN,
INC.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
Minnesota
|
|
001-36046
|
|
41-1301878
|
(State or other jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
incorporation)
|
|
|
|
|
|
|
|
13631 Progress
Boulevard,
Suite 400,
|
|
|
Alachua, Florida
|
|
32615
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code
|
(386) 462-6800
|
(Former name or former address if changed since last report,)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e- 4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which
registered
|
Common Stock, $0.01 par value
|
AXGN
|
The Nasdaq Stock Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01 Other Events.
Oberland Capital exercises its option to purchase $3.5 million of
Company stock
On June 30, 2020 Axogen, Inc. (the “Company”), as borrower, and
certain of the Company’s wholly owned subsidiaries, entered into a
Term Loan Agreement with the lenders party thereto, including TPC
Investments II LP (“TPC”), and Argo SA LLC (“Argo”). TPC and Argo
are each affiliates of Oberland Capital. In connection with the
Term Loan Agreement the Company and TPC entered into an Option
Agreement, pursuant to which the Company granted to TPC the right
to purchase a number of newly issued shares of the Company’s common
stock equal to an aggregate of $3.5 million divided by the Fair
Market Value (as defined in the Option Agreement based upon the 45
day trailing average market value of the Company’s common stock) of
a share of common stock on the date of exercise of such option (the
“Exercise Price”). On December 10, 2020, Oberland Capital exercised
in full its option under the Option Agreement. The Exercise Price
was determined to be $14.13, resulting in gross proceeds to the
Company of approximately $3.5 million and the issuance of 247,699
shares to TPC.
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
AXOGEN, INC.
|
|
|
Date: December 14, 2020
|
By:
|
/s/ Brad Ottinger
|
|
|
Brad Ottinger
|
|
|
General Counsel and Chief Compliance Officer
|